Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: Initial patency and influence of maintained infusion on reocclusion rate
References (29)
- et al.
Double-blind, randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction
Lancet
(1985) - et al.
Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction
Lancet
(1985) - et al.
Evaluation of the effectiveness of intracoronary streptokinase infusion in acute myocardial infarction: post procedure management and hospital course in 204 patients
Am Heart J
(1981) - et al.
Intracoronary thrombolysis in acute myocardial infarction: correlations among serum enzyme, scintigraphic and hemodynamic findings
Am J Cardiol
(1982) - et al.
Intracoronary streptokinase in clinical practice
Am Heart J
(1982) - et al.
Percutaneous transluminal coronary angioplasty after thrombolytic therapy: a prospective controlled randomized trial
JACC
(1986) - et al.
Improvement in regional and global left ventricular function after intracoronary thrombolysis: assessment with two-dimensional echoeardiography
Am J Cardiol
(1984) - et al.
Influence of baseline ejection fraction and success of thrombolysis on mortality and ventricular function after acute myocardial infarction
Am J Cardiol
(1984) - et al.
Follow-up after coronary arterial reperfusion with intravenous streptokinase in relation to residual myocardial infarct artery narrowings
Am J Cardiol
(1985) - et al.
Improved survival after early thrombolysis in acute myocardial infarction. A randomized trial conducted by the ICI in the Netherlands
Lancet
(1985)
Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction
Am J Cardiol
Sustained thrombolysis with DNA-recombinant tissue-type plasminogen activator in rabbits
Blood
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial
Circulation
The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings
N Engl J Med
Cited by (91)
HTUPA as a new thrombolytic agent for acute myocardial infarction: A multicenter, randomized study
2014, International Journal of CardiologyCitation Excerpt :In our study, the all-cause mortality within 30 d (5.5% in the rt-PA group and 6.3% in the HTUPA group) was lower than that reported by Keeley et al. (9%) in a quantitative review of 23 randomized trials [17]. It is reported that early re-occlusion occurs in 5–30% of patients who undergo successful recanalization by thrombolytic therapy using a first or second-generation agent [18–20]. The relatively short half-life of the currently available thrombolytic agents is the major reason for re-occlusion.
Failed reperfusion after thrombolytic therapy: Recognition and management
2002, Heart and Lung: Journal of Acute and Critical CareCitation Excerpt :TIMI 3 flow in the infarct-related artery after thrombolysis has been associated with decreased mortality when compared with TIMI 2 (slow) flow and TIMI 0 or 1 (none or minimal) flow, as well as decreased incidence of congestive cardiac failure, recurrent ischemia and improved left ventricular ejection fraction.13 However it has been reported that reperfusion fails to occur at all in 25% of patients,6,14,15 and in 50% to 70% of patients at 90 minutes after thrombolytic administration.5,6 It is not entirely clear why some patients fail to reperfuse with thrombolytic therapy.
Ridogrel as an adjunct to thrombolysis in acute myocardial infarction
1995, International Journal of Cardiology